Preexposure prophylaxis for the prevention of human immunodeficiency virus

Obstetrics and Gynecology

Volumn 123, Issue 5, 2014, Pages 1133-1136

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ADENINE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

BEHAVIOR CHANGE; CLINICAL TRIAL (TOPIC); CONDOM USE; GYNECOLOGIST; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MATERNAL CARE; MEDICATION COMPLIANCE; OBSTETRICIAN; PATIENT COUNSELING; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SAFE SEX; SEXUAL PRACTICE; ANALOGS AND DERIVATIVES; ECONOMICS; FEMALE; GYNECOLOGY; HIV INFECTIONS; RISK FACTOR;

ADENINE; ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; FEMALE; GYNECOLOGY; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; RISK FACTORS;

EID: 84900453390     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000446855.78026.21     Document Type: Review

References (11)

1. Centers for Disease Control and Prevention. HIV among women. Atlanta (GA): CDC; 2013. Available at: http://www. cdc.gov/hiv/pdf/risk-women.pdf?. Retrieved January 6, 2014.
2. Routine human immunodeficiency virus screening. Committee Opinion No. 596. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123: 1137-9.
3. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2012;61: 586-9. [PubMed] [Full Text]
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. Partners PrEP Study Team. N Engl J Med 2012;367: 399-410. [PubMed] [Full Text]
5. Celum C, Baeten JM. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther 2012;17: 1483-93. [PubMed] [Full Text]
6. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. TDF2 Study Group. N Engl J Med 2012;367: 423-34. [PubMed] [Full Text]
7. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. FEM-PrEP Study Group. N Engl J Med 2012;367: 411-22. [PubMed] [Full Text]
8. Cohen MS, Baden LR. Preexposure prophylaxis for HIV-- where do we go from here? N Engl J Med 2012;367: 459-61. [PubMed] [Full Text]
9. Gilead Sciences, Inc. Important safety information about TRUVADA for a pre-exposure prophylaxis (PrEP) indication: for healthcare providers. Foster City (CA): Gilead; 2013. Available at: http://start.truvada.com/content/pdf/ Important-Safety-Information-for-Healthcare-Providers. pdf. Retrieved January 6, 2014.
10. Breastfeeding: maternal and infant aspects. ACOG Committee Opinion No. 361. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;109: 479-80. [PubMed] [Obstetrics & Gynecology]
11. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med 2013;44:S125-8. [PubMed] [Full Text]